|
US5364773A
(en)
*
|
1991-03-07 |
1994-11-15 |
Virogenetics Corporation |
Genetically engineered vaccine strain
|
|
US4652639A
(en)
*
|
1982-05-06 |
1987-03-24 |
Amgen |
Manufacture and expression of structural genes
|
|
US4518584A
(en)
*
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US6610476B1
(en)
*
|
1984-08-22 |
2003-08-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
Detection of HIV-1 DNA
|
|
US5032510A
(en)
*
|
1984-09-26 |
1991-07-16 |
Eli Lilly And Company |
Method for expression and secretion in bacillus
|
|
CA1341482C
(en)
*
|
1984-10-31 |
2005-05-10 |
Paul A. Luciw |
Process for preparing fragments of aids-associated retroviruses
|
|
WO1986003224A1
(en)
|
1984-11-29 |
1986-06-05 |
Scripps Clinic And Research Foundation |
Polypeptides and antibodies related to deglycosylated viral glycoproteins
|
|
ATE138100T1
(de)
|
1984-12-24 |
1996-06-15 |
Genentech Inc |
Fusionen von aids-verwandten polypeptiden
|
|
NZ215867A
(en)
|
1985-04-19 |
1989-10-27 |
Hoffmann La Roche |
Aids envelope protein, dna vectors and method of production
|
|
EP0245362B1
(en)
|
1985-10-24 |
1994-06-29 |
Ronald C. Kennedy |
Synthetic peptides and use for diagnosis and vaccination for aids and arc
|
|
EP0242216A1
(en)
|
1986-04-16 |
1987-10-21 |
THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce |
Non-cytopathic clone of Human T-Cell Lymphotropic Virus type III
|
|
AU7786387A
(en)
|
1986-07-21 |
1988-02-10 |
Southwest Foundation For Biomedical Research |
Composition of matter and method of immunizing against viral causative agents of aids and arc
|
|
US4861707A
(en)
*
|
1987-02-02 |
1989-08-29 |
E. I. Du Pont De Nemours And Company |
Human immunodeficiency virus antigen
|
|
US5256767A
(en)
*
|
1987-06-10 |
1993-10-26 |
The Immune Response Corporation |
Retroviral antigens
|
|
IL86832A
(en)
|
1987-06-22 |
2002-09-12 |
Medeva Holdings Bv |
A recombinant DNA molecule containing a nucleotide sequence of part of the region encoding HBV pre-1s, an immunogenic particle containing multiple peptide monomers containing a pre-s1 epitope and pharmaceutical preparations containing it
|
|
US5637677A
(en)
*
|
1987-07-16 |
1997-06-10 |
The Trustees Of The University Of Pennsylvania |
Biologically active compounds and methods of constructing and using the same
|
|
US5128319A
(en)
*
|
1987-08-28 |
1992-07-07 |
Board Of Regents, The University Of Texas System |
Prophylaxis and therapy of acquired immunodeficiency syndrome
|
|
WO1989002277A2
(en)
|
1987-08-28 |
1989-03-23 |
Board Of Regents, The University Of Texas System |
Prophylaxis and therapy of acquired immunodeficiency syndrome
|
|
EP0347435A4
(en)
|
1987-09-04 |
1991-11-21 |
Biogen, Inc. |
Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
|
|
US5879907A
(en)
*
|
1987-09-14 |
1999-03-09 |
Skandigen Ab |
Artificial gene coding for authentic human serum albumin, use thereof and method
|
|
NZ226414A
(en)
|
1987-10-02 |
1992-07-28 |
Genentech Inc |
Cd4 peptide adhesion variants and their preparation and use
|
|
IL87902A0
(en)
|
1987-10-08 |
1989-03-31 |
Dana Farber Cancer Inst Inc |
Soluble human cd4 fragments and applications thereof
|
|
US5712088A
(en)
*
|
1987-11-18 |
1998-01-27 |
Chiron Corporation |
Methods for detecting Hepatitis C virus using polynucleotides specific for same
|
|
US5683864A
(en)
*
|
1987-11-18 |
1997-11-04 |
Chiron Corporation |
Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
|
|
US5714596A
(en)
*
|
1987-11-18 |
1998-02-03 |
Chiron Corporation |
NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
|
|
CA1340748C
(en)
|
1988-07-13 |
1999-09-14 |
Stephen Oroszlan |
Synthetic hiv protease gene and method for its expression
|
|
WO1990002568A1
(en)
|
1988-09-13 |
1990-03-22 |
Chiron Corporation |
Hiv-1 envelope muteins lacking hypervariable domains
|
|
WO1990003984A1
(en)
|
1988-10-03 |
1990-04-19 |
Repligen Corporation |
Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
|
|
CA2003383A1
(en)
*
|
1988-11-23 |
1990-05-23 |
Sushil G. Devare |
Synthetic dna derived recombinant hiv antigens
|
|
US5082767A
(en)
*
|
1989-02-27 |
1992-01-21 |
Hatfield G Wesley |
Codon pair utilization
|
|
IL93682A
(en)
|
1989-03-16 |
1996-06-18 |
Yeda Res & Dev |
Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
|
|
WO1990011359A1
(en)
|
1989-03-20 |
1990-10-04 |
Whitehead Institute For Biomedical Research |
Intracellular method of inhibiting hiv in mammalian cells
|
|
US6214804B1
(en)
*
|
1989-03-21 |
2001-04-10 |
Vical Incorporated |
Induction of a protective immune response in a mammal by injecting a DNA sequence
|
|
DK0737750T3
(da)
|
1989-03-21 |
2003-09-01 |
Vical Inc |
Ekspression af exogene polynucleotidsekvenser i vertebrater
|
|
WO1990012094A1
(en)
|
1989-04-05 |
1990-10-18 |
The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce |
A clone of double-stranded rna virus and applications thereof
|
|
EP0431128B1
(en)
|
1989-06-01 |
2003-03-26 |
Applied Biotechnology, Inc. |
Vector coding for self-assembled, defective, non-self-propagating viral particles
|
|
US5130247A
(en)
*
|
1989-09-19 |
1992-07-14 |
Merck & Co., Inc. |
Expression of fusion protein of HIV envelope and HBsAG
|
|
DE69019291T2
(de)
*
|
1989-10-23 |
1995-09-21 |
F. Hoffmann-La Roche Ag, Basel |
Synthetische HTLV-I Hüll-Peptide.
|
|
US5876724A
(en)
*
|
1990-03-19 |
1999-03-02 |
Institut Pasteur |
Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
|
|
ATE183235T1
(de)
|
1990-03-21 |
1999-08-15 |
Wolf Hans Joachim Prof Dr |
Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon
|
|
US5840313A
(en)
*
|
1990-09-27 |
1998-11-24 |
Syntello Vaccine Development Kb |
Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
|
|
DE69129154T2
(de)
*
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
PT100090A
(pt)
*
|
1991-02-04 |
1993-07-30 |
Univ Saskatchewan |
Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
|
|
JPH06508821A
(ja)
*
|
1991-03-07 |
1994-10-06 |
セラジュン インク |
ウイルス病治療のための細胞表面受容体を標的とする分子の使用
|
|
US5558865A
(en)
*
|
1991-08-22 |
1996-09-24 |
Nissin Shokuhin Kabushiki Kaisha |
HIV immunotherapeutics
|
|
DK0608261T3
(da)
*
|
1991-09-13 |
2003-03-17 |
Chiron Corp |
Sammensætninger med immunreaktivt hepatitis C virus polypeptid
|
|
US6025126A
(en)
*
|
1991-10-28 |
2000-02-15 |
Arch Development Corporation |
Methods and compositions for the detection of chromosomal aberrations
|
|
US6174666B1
(en)
*
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
|
CA2135646A1
(en)
|
1992-05-11 |
1993-11-25 |
Kenneth G. Draper |
Method and reagent for inhibiting viral replication
|
|
US5663169A
(en)
*
|
1992-08-07 |
1997-09-02 |
Merck & Co., Inc. |
Benzoxazinones as inhibitors of HIV reverse transcriptase
|
|
DE4228458A1
(de)
*
|
1992-08-27 |
1994-06-01 |
Beiersdorf Ag |
Multicistronische Expressionseinheiten und deren Verwendung
|
|
FR2695563B1
(fr)
*
|
1992-09-11 |
1994-12-02 |
Pasteur Institut |
Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
|
|
US6004763A
(en)
*
|
1992-09-11 |
1999-12-21 |
Institut Pasteur |
Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
|
|
US5686078A
(en)
*
|
1992-09-14 |
1997-11-11 |
Connaught Laboratories, Inc. |
Primary and secondary immunization with different physio-chemical forms of antigen
|
|
CA2105629A1
(en)
*
|
1992-09-14 |
1994-03-15 |
Robert S. Becker |
Potentiation of immunogenic response
|
|
US5304472A
(en)
*
|
1992-11-20 |
1994-04-19 |
Genentech, Inc. |
Method of controlling polypeptide production in bacterial cells
|
|
ATE199392T1
(de)
*
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
US6140059A
(en)
*
|
1993-01-16 |
2000-10-31 |
Schawaller; Manfred |
Methods for the obtention of human immunodeficiency virsus Type 1 envelope glycoproteins in native and oligomeric form employing recombinant chimeric antigens containing collagenase recognition sites.
|
|
US5593972A
(en)
*
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
|
JP4108118B2
(ja)
|
1993-03-26 |
2008-06-25 |
ジェン−プローブ・インコーポレイテッド |
ヒト・免疫不全ウイルス1型の検出
|
|
US5419900A
(en)
*
|
1993-05-19 |
1995-05-30 |
The United States Of America As Represented By The Department Of Of Health And Human Services |
Immunologic enhancement with intermittent interleukin-2 therapy
|
|
WO1994028929A1
(en)
*
|
1993-06-07 |
1994-12-22 |
Genentech, Inc. |
Hiv envelope polypeptides
|
|
AU693098B2
(en)
*
|
1993-06-09 |
1998-06-25 |
Connaught Laboratories Limited |
Tandem synthetic HIV-1 peptides
|
|
US5614413A
(en)
*
|
1993-07-01 |
1997-03-25 |
The Uab Research Foundation |
Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
|
|
US5955342A
(en)
*
|
1994-08-15 |
1999-09-21 |
Connaught Laboratories Limited |
Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
|
|
US6291157B1
(en)
*
|
1998-02-23 |
2001-09-18 |
Connaught Laboratories Limited |
Antigenically-marked non-infectious retrovirus-like particles
|
|
US6080408A
(en)
*
|
1994-08-22 |
2000-06-27 |
Connaught Laboratories Limited |
Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
|
|
US5795737A
(en)
*
|
1994-09-19 |
1998-08-18 |
The General Hospital Corporation |
High level expression of proteins
|
|
US5786464C1
(en)
*
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
US5550280A
(en)
*
|
1994-11-30 |
1996-08-27 |
Uniroyal Chemical Ltd./ Uniroyal Chemical Ltee |
Hindered aromatic ester compounds useful as anti-viral agents
|
|
US5846456A
(en)
*
|
1996-01-17 |
1998-12-08 |
National Science Council |
Method of making gradient index optical element
|
|
CU22559A1
(es)
*
|
1996-01-17 |
1999-05-03 |
Ct Ingenieria Genetica Biotech |
Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
|
|
US5741492A
(en)
*
|
1996-01-23 |
1998-04-21 |
St. Jude Children's Research Hospital |
Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
|
|
US6087486A
(en)
*
|
1996-01-29 |
2000-07-11 |
The Trustees Of The University Of Pennsylvania |
Nucleotide sequences encoding vpr receptor protein
|
|
US6060587A
(en)
*
|
1996-01-29 |
2000-05-09 |
The Trustees Of The University Of Pennsylvania |
Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
|
|
US5951975A
(en)
*
|
1996-06-28 |
1999-09-14 |
University Of Pittsburgh |
Induction of CTLs specific for natural antigens by cross priming immunization
|
|
CA2265889A1
(en)
*
|
1996-09-06 |
1998-03-12 |
The Regents Of The University Of California |
E25a protein, methods for production and use thereof
|
|
US6114148C1
(en)
*
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
US6139833A
(en)
*
|
1997-08-08 |
2000-10-31 |
Lexicon Genetics Incorporated |
Targeted gene discovery
|
|
US5858675A
(en)
*
|
1997-05-13 |
1999-01-12 |
Incyte Pharmaceuticals, Inc. |
Double-stranded RNA-binding protein
|
|
US6099847A
(en)
*
|
1997-05-15 |
2000-08-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Chimeric Gag pseudovirions
|
|
FR2768621B1
(fr)
*
|
1997-09-22 |
2000-04-07 |
Oreal |
Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
|
|
US5932442A
(en)
*
|
1997-09-23 |
1999-08-03 |
Incyte Pharmaceuticals, Inc. |
Human regulatory molecules
|
|
US5932445A
(en)
*
|
1997-11-07 |
1999-08-03 |
Incyte Pharmaceuticals, Inc. |
Signal peptide-containing proteins
|
|
IT1297090B1
(it)
*
|
1997-12-01 |
1999-08-03 |
Barbara Ensoli |
Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
|
|
WO1999053046A2
(en)
*
|
1998-04-14 |
1999-10-21 |
Chiron Corporation |
Noncloning technique for expressing a gene of interest
|
|
US6090388A
(en)
*
|
1998-06-20 |
2000-07-18 |
United Biomedical Inc. |
Peptide composition for prevention and treatment of HIV infection and immune disorders
|
|
AU2221600A
(en)
*
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
US7935805B1
(en)
*
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
ATE384795T1
(de)
*
|
1998-12-31 |
2008-02-15 |
Novartis Vaccines & Diagnostic |
Modifizierte hiv env polypeptide
|
|
EP1141314A2
(en)
*
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
EP1228237A1
(en)
*
|
1999-11-01 |
2002-08-07 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
|
WO2001045748A1
(en)
*
|
1999-12-22 |
2001-06-28 |
Merck & Co., Inc. |
Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
|
|
US7622125B2
(en)
*
|
2004-05-05 |
2009-11-24 |
Novartis Vaccines And Diagnostics, Inc. |
Polycistronic HIV vector constructs
|